Lawmakers Begin Lobbying CMS Over Medicare Drug Formularies
This article was originally published in The Pink Sheet Daily
Executive Summary
Sen. Smith (R-Ore.) expresses concern about classification of antidepressants in U.S. Pharmacopeia's Medicare formulary guidelines during Senate Finance Committee hearing.
You may also be interested in...
Lilly Honors Oregon Senator For Mental Health Legislation
Lilly's 2004 Helping Move Lives Forward Reintegration Government Honorary Award gives $5,000 to an advocacy program of the recipient's choice. Sen. Gordon Smith (R-Ore.) sponsored the Garrett Lee Smith Memorial Act, which boosts suicide prevention programs.
Lilly Honors Oregon Senator For Mental Health Legislation
Lilly's 2004 Helping Move Lives Forward Reintegration Government Honorary Award gives $5,000 to an advocacy program of the recipient's choice. Sen. Gordon Smith (R-Ore.) sponsored the Garrett Lee Smith Memorial Act, which boosts suicide prevention programs.
USP Responding To Congress' Questions On Medicare Formulary Guidelines
The U.S. Pharmacopeia has provided information to two congressional committees as it moves toward finalizing its model formulary guidelines for the Medicare drug benefit. USP emphasizes that no decision on the final structure of the guidelines has been made; final recommendations to CMS are expected by year-end.